Articles from Aptar

AptarGroup, Inc. (NYSEATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases.

Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a strategic partnership with the Chiesi Group, the international research-focused biopharmaceutical and healthcare group, to bring to market a disease management platform for asthma and chronic obstructive pulmonary disease (COPD). Aptar Digital Health is a division of Aptar Pharma, part of Aptar (NYSEATR).

Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSEATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.